Bevacizumab 100 MG & 400 MG (Bevastim)

Important: Bevacizumab is a complex biologic (monoclonal antibody), not a small-molecule generic. Terms such as “biosimilar” or “equivalent” for a biologic refer to demonstrated similarity in structure, function, and clinical performance under an appropriate regulatory pathway — please confirm and disclose the specific comparability/biosimilarity data and approval basis for Bevastim, as this differs materially from standard small-molecule bioequivalence and should be represented accurately to buyers and prescribers.

Basic Product Information of Bevastim (Bevacizumab) 100mg & 400mg

Brand Name	Bevastim (Bevacizumab) — please confirm brand/generic naming before publishing; see note above
Generic Name	Bevacizumab INN
Drug Class	Anti-VEGF Monoclonal Antibody (Angiogenesis Inhibitor)
Available Strengths	100mg/4mL and 400mg/16mL (25mg/mL concentration in each vial)
Formulation	Sterile Solution for Intravenous Infusion (Injection Vial)
Pack Size	1’s (single vial per pack), available in 100mg and 400mg vial sizes. The number and combination of vials used per infusion depends on the patient’s body weight and prescribed dose.
Primary Indication	Multiple Solid Tumours, in Combination with Chemotherapy or Other Anticancer Agents (see Indications below)
Regulatory Approvals	Originator (Avastin) USFDA and EMA Approved across numerous oncology indications. Please confirm the specific regulatory status and approved indications for Bevastim itself.
Originator Brand	Avastin by Genentech/Roche
Manufacturer	[Manufacturer name to be confirmed], Bangladesh
Global Supplier	Mediaid Pharmacy, Worldwide Shipping Available
Registration	Registered in Bangladesh
Storage Conditions	Store refrigerated between 2°C and 8°C, in the original carton to protect from light. Do not freeze or shake. Requires an unbroken cold chain from manufacture through delivery — please confirm cold-chain shipping capability before ordering.

How Bevastim (Bevacizumab) Works

Bevastim contains Bevacizumab, a monoclonal antibody that binds to and neutralises VEGF (vascular endothelial growth factor), a signalling protein that tumours release to trigger the growth of new blood vessels, a process known as angiogenesis. Tumours depend on this new blood supply for the oxygen and nutrients they need to grow beyond a small size and to spread to other parts of the body.

By binding VEGF before it can reach its receptors on blood vessel cells, Bevastim blocks new blood vessel formation around the tumour, helping to starve it of blood supply and slow its growth. This is a different mechanism from conventional chemotherapy, which is why Bevastim is typically used in combination with chemotherapy or other targeted or immunotherapy agents rather than as a stand-alone treatment.

Bevastim is administered as an intravenous infusion by trained healthcare professionals in a hospital or oncology infusion setting. The first infusion is typically given over about 90 minutes; if well tolerated, later infusions may be given more quickly, per the treating institution’s protocol. It is not self-administered and is not intended for home use.

Indications for Bevastim (Bevacizumab)

The originator molecule, Bevacizumab, has been approved across a range of cancers, always in combination with chemotherapy or another anticancer agent. Approved indications, lines of therapy, and combination partners vary by country and are updated periodically; representative tumour types include:

Metastatic Colorectal Cancer In combination with fluoropyrimidine-based chemotherapy, for metastatic disease. Not indicated for adjuvant use after surgery.	Non-Squamous NSCLC In combination with chemotherapy, for unresectable, locally advanced, recurrent, or metastatic non-squamous non-small cell lung cancer.
Recurrent Glioblastoma; Renal Cell Carcinoma For adults with recurrent glioblastoma, and for metastatic renal cell carcinoma in combination with interferon alfa.	Cervical, Ovarian, and Liver Cancer Persistent, recurrent, or metastatic cervical cancer with chemotherapy; epithelial ovarian, fallopian tube, or primary peritoneal cancer with chemotherapy in various settings; and unresectable or metastatic hepatocellular carcinoma in combination with an anti-PD-L1/PD-1 agent.

This list is representative, not exhaustive. The exact approved indication, line of therapy, and combination regimen for any individual patient must be confirmed against current, country-specific prescribing information and determined by the treating oncologist.

Benefits of Bevastim (Bevacizumab)

Distinct Anti-Angiogenic Mechanism Works by cutting off tumour blood supply rather than directly killing cells, complementing chemotherapy, targeted therapy, and immunotherapy.	Broad Oncology Applicability The originator molecule is approved across numerous solid tumour types, one of the most widely used anti-angiogenic agents in oncology.	Two Vial Sizes for Flexible Dosing Available as 100mg and 400mg vials, allowing hospital pharmacies to prepare individualised, weight-based doses with less product wastage.
Long-Established Clinical Track Record The originator has been in oncology use since 2004, giving prescribers extensive real-world experience with its efficacy and safety profile.	Cost-Accessible Option Positioned as a more affordable route to anti-VEGF therapy than the originator brand, subject to confirmation of comparability data.	WHO-GMP and cGMP Certified Manufactured under strict WHO-GMP, cGMP, and ISO-certified standards, ensuring every batch of Bevastim meets consistent quality and safety requirements.

Administration of Bevastim (Bevacizumab)

Monitoring and Other Precautions

Beyond the boxed warning risks, regular monitoring during Bevastim treatment includes blood pressure, given the risk of significant, sometimes severe hypertension, and urine protein, given the risk of proteinuria and, rarely, nephrotic syndrome. Your healthcare provider will also watch for arterial and venous thromboembolic events (such as stroke, heart attack, or blood clots), signs of heart failure particularly if combined with anthracycline chemotherapy, rare posterior reversible encephalopathy syndrome (PRES), and infusion-related reactions during and after each dose. Report any severe abdominal pain, unusual bleeding, coughing up blood, chest pain, sudden severe headache, vision changes, seizures, or leg swelling to the care team immediately.

Drug Interactions and Important Information

As a monoclonal antibody, Bevacizumab is not metabolised through the cytochrome P450 system, so classic small-molecule drug interactions are not expected. However, combining Bevastim with anthracycline-based chemotherapy may increase the risk of cardiac toxicity, and combining it with sunitinib or other agents affecting wound healing or blood pressure may compound those specific risks. Bevastim is not indicated for use in squamous NSCLC due to a substantially higher risk of serious pulmonary haemorrhage in that tumour type.

Women of childbearing potential should use effective contraception during treatment and for 6 months after the final dose, given the risk of fetal harm and reported effects on ovarian function. Always inform your physician of all medications, prior surgery, and planned procedures before starting Bevastim.

Side Effects and Precautions

Common Side Effects Epistaxis (nosebleed), usually minor Hypertension Headache Proteinuria Taste alteration and dry skin Rhinitis Back pain and fatigue

Serious Warnings and Precautions Gastrointestinal perforation and fistula formation (Boxed Warning). Wound healing and surgical complications (Boxed Warning). Severe or fatal haemorrhage (Boxed Warning). Arterial and venous thromboembolic events, including stroke and heart attack. Severe hypertension, nephrotic syndrome, and posterior reversible encephalopathy syndrome. Embryo-fetal toxicity and ovarian failure risk.

Who Should Use Bevastim (Bevacizumab)?

Bevastim is intended for adult patients with an eligible, confirmed cancer diagnosis matching one of the approved indications for Bevacizumab, as determined by an oncologist, and always given alongside chemotherapy or another approved combination agent. It is administered exclusively in a hospital or specialist oncology infusion setting by trained healthcare professionals equipped to manage bleeding, perforation, and wound-related complications. A careful surgical history and baseline blood pressure, urine protein, and cardiovascular assessment are required before starting treatment.

Manufacturer

Bevastim (Bevacizumab) is manufactured in Bangladesh under strict WHO-GMP, cGMP, and ISO-certified standards. [Please confirm the exact manufacturer name, and the specific comparability/biosimilarity data or approval basis, so this section and the claims above can be made fully accurate before publishing.]

Global Supplier: Mediaid Pharmacy with Worldwide Shipping

Mediaid Pharmacy is a trusted global supplier of specialty oncology medications. We ensure Bevastim (Bevacizumab) is accessible to hospitals and healthcare providers worldwide through reliable, cold-chain worldwide shipping. Whether you are located in South Asia, the Middle East, Africa, Europe, or beyond, Mediaid Pharmacy provides fast and reliable delivery with full order support. Contact us directly via WhatsApp, phone, or WeChat for pricing, availability, and delivery enquiries.

Why Choose Bevastim (Bevacizumab) from Mediaid Pharmacy?

Bevastim offers hospitals and oncology centres a route to anti-VEGF therapy that reflects the same active substance and mechanism of action as Avastin by Genentech/Roche, at a more accessible price point. Manufactured under WHO-GMP and cGMP standards and distributed globally by Mediaid Pharmacy, Bevastim aims to widen access to angiogenesis-inhibiting cancer therapy for cancer centres worldwide. As with any biologic product, institutions should review the specific comparability data supporting Bevastim before adoption into clinical use.

Frequently Asked Questions About Bevastim (Bevacizumab)